Potent	O
antibacterial	O
activity	O
of	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
with	O
selective	O
action	O
against	O
Helicobacter	O
pylori	O
.	O

Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
,	O
was	O
investigated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
.	O

Unlike	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
,	O
the	O
compound	O
had	O
no	O
activity	O
against	O
common	O
aerobic	O
and	O
anaerobic	O
bacteria	O
other	O
than	O
Helicobacter	O
pylori	O
.	O

The	O
minimum	O
inhibitory	O
concentration	O
of	O
Y	O
-	O
754	O
against	O
H	O
.	O
pylori	O
,	O
at	O
0	O
.	O
025	O
microg	O
/	O
ml	O
,	O
was	O
nearly	O
equal	O
to	O
that	O
of	O
amoxicillin	O
and	O
clarithromycin	O
.	O

The	O
respective	O
concentrations	O
of	O
Y	O
-	O
754	O
,	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
required	O
to	O
inhibit	O
90	O
%	O
of	O
39	O
isolates	O
of	O
H	O
.	O
pylori	O
were	O
0	O
.	O
05	O
,	O
0	O
.	O
39	O
,	O
6	O
.	O
25	O
,	O
and	O
25	O
microg	O
/	O
ml	O
,	O
indicating	O
the	O
potent	O
activity	O
of	O
Y	O
-	O
754	O
,	O
including	O
activity	O
against	O
clarithromycin	O
-	O
and	O
metronidazole	O
-	O
resistant	O
strains	B-Cell
.	O

The	O
anti	O
-	O
H	O
.	O
pylori	O
activity	O
of	O
Y	O
-	O
754	O
was	O
potent	O
even	O
at	O
pH	O
5	O
.	O
5	O
and	O
was	O
bactericidal	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
microg	O
/	O
ml	O
and	O
above	O
.	O

Exposure	O
of	O
H	O
.	O
pylori	O
to	O
Y	O
-	O
754	O
did	O
not	O
result	O
in	O
the	O
induction	O
of	O
drug	O
-	O
resistant	O
mutation	O
.	O

Oral	B-Organism_subdivision
administration	O
(	O
10	O
mg	O
/	O
kg	O
twice	O
a	O
day	O
for	O
7	O
days	O
)	O
to	O
Mongolian	O
gerbils	O
infected	O
with	O
strain	B-Cell
ATCC	O
43504	O
demonstrated	O
that	O
Y	O
-	O
754	O
was	O
effective	O
in	O
H	O
.	O
pylori	O
eradication	O
and	O
that	O
its	O
eradication	O
efficacy	O
increased	O
in	O
line	O
with	O
the	O
progress	O
of	O
damage	O
to	O
the	O
gastric	B-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
caused	O
by	O
H	O
.	O
pylori	O
infection	O
.	O

Y	O
-	O
754	O
was	O
also	O
efficacious	O
in	O
the	O
treatment	O
of	O
infection	O
by	O
the	O
clarithromycin	O
-	O
resistant	O
strain	B-Cell
OIT	O
-	O
36	O
.	O

The	O
results	O
obtained	O
lead	O
to	O
the	O
expectation	O
that	O
the	O
new	O
benzimidazole	O
Y	O
-	O
754	O
will	O
,	O
in	O
the	O
near	O
future	O
,	O
be	O
used	O
for	O
H	O
.	O
pylori	O
eradication	O
therapy	O
in	O
peptic	B-Pathological_formation
ulcer	I-Pathological_formation
patients	O
.	O

